Effects of Air Purifiers on Patients with Allergic Rhinitis: a Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study by 박경희 et al.
689www.eymj.org
INTRODUCTION
Indoor air pollution is a critical issue, with up to 90% of daily 
living currently taking place indoors.1 In this regard, children 
and elderly adults, often confined to their homes, are espe-
cially vulnerable.2 Indoor air in schools and workplaces can be 
a factor affecting respiratory health.3,4 Among known air pol-
lutants, particulate matter (PM) is an acknowledged hazard 
with diverse effects on human health. Ambient PM exposure 
may adversely impact various cardiopulmonary conditions, in-
cluding allergic airway disease.5,6 
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Purpose: Exposure to particulate matter (PM) is a well-known risk factor in the triggering and exacerbation of allergic airway dis-
ease. Indoor environments, where people spend most of their time, are of utmost importance. To assess the effects of air purifiers 
[equipped with high-efficiency particulate air (HEPA) filters] on allergic rhinitis (AR) in adult patients, we performed a multicenter, 
randomized, double-blind, and placebo-controlled study.
Materials and Methods: Patients with house dust mite (HDM)-induced AR were randomly assigned to either active or mockup 
(placebo) air-purification groups. Two air purifiers (placed in living room and bedroom) were operated for 6 weeks in each home 
environment. The primary study endpoint was to achieve improvement in AR symptoms and medication scores. Secondary end-
points were to achieve improvement in the quality of life (QoL) and visual analog scale (VAS) scores, as well as in the indoor (bed-
room and living room) concentrations of PM2.5 and PM10. 
Results: After 6 weeks of air purifier use, medication scores improved significantly in the active (vs. placebo) group, although sub-
jective measures (symptoms, VAS, and QoL scores) did not differ. Bedroom PM2.5 concentrations initially exceeded living room or 
outdoor levels, but declined (by up to 51.8%) following active purifier operation. Concentrations of PM2.5 in living room and PM10 
in bedroom and living room were also significantly reduced through active purification.
Conclusion: The use of air purifiers with HEPA filters significantly reduced medication requirements for patients with HDM-in-
duced AR and significantly lowered indoor PM2.5 concentrations, regardless of room placement. Active intervention to reduce 
household air pollutants may help improve allergic airway disease (clinicaltrials.gov NCT03313453).
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PM concentrations vary considerably by country and city, 
based on geopolitical location and socio-economic status. Ac-
cording to the World Health Organization air quality guide-
lines (WHO AQG), 24-hour concentrations of <50 μg/m3 for 
PM ≤10 μm (PM10) and <25 μg/m3 for PM ≤2.5 μm (PM2.5) are 
recommended (annual mean: PM10, <20 μg/m3; PM2.5, <10 μg/
m3).7 However, the average annual PM10 level in the Seoul 
metropolitan area, which has climbed steadily since 2012 and 
now stands at 51.0 μg/m3, exceeds the WHO AQG limit.8
It has been shown that the use of an air purifier equipped 
with a high-efficiency particulate air (HEPA) filter to reduce 
indoor air pollution helps control allergic diseases. A number 
of reports have indicated that air purifiers are beneficial for pa-
tients with allergic rhinitis (AR),9-11 atopic dermatitis,12 and asth-
matic children.13,14 In addition, air purifiers are credited with 
removing pollen, fungal spores,15 house dust-mite (HDM) al-
lergens,10 and dog allergens.16 
Previous studies evaluating the efficacy of air purifiers in re-
lieving AR have focused solely on allergen removal, conduct-
ed research in lesser polluted countries, or had flawed study 
design (i.e., too few participants, single-center recruitment, or 
absence of a control/placebo group). This multicenter, ran-
domized, double-blind, and placebo-controlled study of air pu-
rifiers in patients with AR was undertaken in an effort to over-
come such limitations. 
MATERIALS AND METHODS
Study design and ethical statement
By design, this was a 6-week multicenter, double-blind, and pla-
cebo-controlled study conducted at two centers in South Ko-
rea: Allergy and Asthma Center of Yonsei University in Seoul 
and Chonnam National University Medical School in Gwangju 
(clinicaltrials.gov NCT03313453). Our interventional protocol 
was approved by the Institutional Review Boards of Yonsei 
University Health System (Approval no. 4-2017-0588) and 
Chonnam National University Hospital (Approval no. CNUH- 
2017-184). The period of purifier operation lasted from late au-
tumn to early winter in South Korea, out of pollen season with-
out indoor heating (from October to November). The study 
was conducted in all of the enrolled individuals during the 
same 6-week periods.
Inclusion and exclusion criteria for enrollment
Inclusion criteria were as follows: 1) patients with AR, ages 18– 
65 years; 2) persistent moderate-to-severe AR sensitized to 
HDM, with retrospective rhinoconjunctivitis total symptom 
score (RRCTSS) ≥8; and 3) and written consent of voluntary 
participants. The severity of rhinitis was determined by RRCTSS 
during the month prior to the start of the study, based on six 
parameters: sneezing, rhinorrhea, nasal itchiness, nasal ob-
struction, ocular itchiness, and watery eyes. Each symptom was 
scored (0–3 points) as follows: 0, no symptom; 1, mild (mild 
symptoms/signs of rhinitis, well-controlled); 2, moderate 
(moderate symptoms/signs, difficult to control and interrupt-
ing daily activities or sleep); or 3, severe (severe symptoms/
signs, difficult to control and interfering with daily activities or 
sleep). 
The reasons for study exclusion were as follows: 1) seasonal 
allergies sensitized to tree, grass, or weed pollen; 2) rhinitis 
due to other causes (vasomotor, infectious, gustatory, or drug 
induced); 3) substantial and potentially obstructive nasal de-
fects, such as deviated nasal septum; 4) chronic use of systemic 
corticosteroids (continuous for ≥3 months in the 12 months 
prior to study); 5) planned move or residential change within 
study period; 6) current air purifier usage; and 7) exposure to 
indoor tobacco smoke.
Sensitization profiles were determined by skin-prick test 
(SPT) and serum specific immunoglobulin E (IgE) test. Inhal-
ant allergens (53 types), including tree, grass, weed pollen, 
HDMs, animal danders, molds, insects [Allergopharma (Ham-
burg, Germany) or Hollister-Stier (Spokane, WA, USA)], were 
tested; as well as controls [negative: normal saline with 0.3% 
phenol and 50% glycerol; positive: 0.1% histamine (Allergy 
Therapeutics, West Sussex, UK)]. SPTs were considered positive 
if wheal diameters at allergen sites were >3 mm on average. 
AdvanSure AlloScreen (LG Life Sciences, Seoul, South Korea) 
or ImmunoCAP (Thermo Fisher Scientific, Waltham, MA, 
USA) assays were peformed to detect specific IgE in serum. 
Values >0.35 kUA/L were interpreted as positive. Paranasal si-
nus series or Waters’ view x-rays were obtained to delineate 
nasal defects, and blood eosinophil counts were measured. 
A total of 44 patients were randomly assigned to either active 
purifier (AP, n=22) or mockup (placebo) purifier (MP, n=22) 
groups. Randomization was 1:1 via computer-generated sched-
ule (in the order registered) and was carried out by a non-par-
ticipating third party. Results were undisclosed until the end 
of study period. During the 6-week trial, patients had unre-
stricted access to medications previously used for rhinitis. Hos-
pital visits were mandatory for all participants before, during, 
and after air purifier operation. 
Air purifiers 
Two air purifiers (LG Electronics, Seoul, South Korea) were pro-
vided per subject (Supplementary Fig. 1, only online). High-ca-
pacity purifier (capacity: 91 m2) was operated in the living 
room (AS281DAW, LG Electronics) (Supplementary Fig. 1A, 
only online), and low-capacity purifier (capacity: 58 m2) was 
operated in the bedroom (AS181DAW, LG Electronics) (Sup-
plementary Fig. 1B, only online). The purifier instructor team 
guided the subjects to the optimal position and orientation to 
operate the air purifiers. Both machines ran continuously for 
24 hours/day without interruption during 6 weeks of research, 
as confirmed by the LG Electronics study center via remote 
(Wi-Fi) monitoring. Purifiers of the AP group were equipped 
691
Kyung Hee Park, et al.
https://doi.org/10.3349/ymj.2020.61.8.689
with HEPA filters (Supplementary Fig. 1C, only online, green-
colored cylindrical apparatus), whereas units of MP members 
were operated without HEPA filters. Attached stickers secured 
the units, preventing secretive access to HEPA filters, and 
blinding was maintained until the end of the study. All of the 
participants were provided with a manual of the operation, pre-
cautions, and emergency contact number for error. 
Indoor and outdoor air analyses 
Indoor PM2.5, PM10 concentrations was measured by PPD4260B 
sensor (Shineyei, Kobe, Japan) equipped in the purifiers.17 De-
tection limits of the sensor were as follows: PM size, 1.0 μm; 
range of PM concentrations, 8-999 μg/m3. Capability of the sen-
sor installed inside the purifiers was also well-correlated with 
that of Portable Aerosol Spectrometer Model 1.109 (GRIMM, 
Ainring, Germany, data not shown). For this study, we mea-
sured and collected 2.5 μm and 10 μm-sized PM concentra-
tions using the optical particle measurement method. 
The status of purifier operation and PM concentrations (liv-
ing rooms and bedrooms) were sent to LG Electronics in real-
time via Wi-Fi network machine mounted inside purifiers. All 
subjects agreed to wireless internet transmission of household 
PM concentrations and purifier operational updates to autho-
rized centers. Display areas of all purifiers were blinded before 
study initiation. As a result, neither participant nor study per-
sonnel (medical staffs, clinical coordinator, LG researcher, and 
statistician) were not aware of the PM levels in their rooms un-
til the end of the study.
Outdoor concentrations of PM2.5 and PM10 were recorded us-
ing the Air Korea monitoring system (https://www.airkorea.
or.kr/eng/), a service of the Korean Ministry of Environment 
and Korea Environment Corporation that publicly dissemi-
nates real-time air quality data online. Measurements obtained 
at observatory stations nearest to the various households were 
used for analysis. Locations of observatories and home sites are 
shown in Supplementary Fig. 2 (only online). 
Primary and secondary endpoints
Clinical manifestations of AR were monitored at 0, 3, and 6 
weeks using questionnaires based on the averages of the prior 
week. Each patient received a diary outlining questions perti-
nent to their symptoms, medication use, etc., and was asked to 
record daily, starting from 1 week before the beginning of pu-
rifier operation. All of the subjects were required to bring dia-
ries to each of their three hospital visits. 
The primary endpoint of the study was to achieve improve-
ment of AR symptoms and medication scores. Four nasal symp-
toms (itchy nose, sneezing, runny nose, and blocked nose) 
were scored using a 4-point scale ranging from 0 (no symp-
tom) to 3 (severe symptoms, interfering with daily activities or 
sleeping). Daily average medication scores were also based on 
a 3-point-scale: 1 (oral or topical antihistamine use); 2 (intra-
nasal corticosteroid use, with or without anti-histamine); and 
3 (oral corticosteroid use, with or without intra-nasal corticoste-
roid or anti-histamine).18 Secondary endpoints were improve-
ment in the quality of life (QoL) questionnaire scores (admin-
istered in Korean language);19 visual analog scale (VAS) scores 
(0 to 10, larger numbers indicating more severe symptoms); 
and indoor PM concentration (PM2.5 and PM10), PM10 signify-
ing coarse particles (2.5–10 μm) and PM2.5 representing fine 
particulates (<2.5 μm).
Statistical analysis
Sample size was calculated using PASS v12 (NCSS LLC, 
Kaysville, UT, USA). A sample size of 22 for each of the two 
groups (1:1 allocation, 5% expected drop-out rate) was deter-
mined to achieve an 80% power, assuming a change in total 
nasal symptom score of 2.5 (as in a previous study),9 standard 
deviations of 2.3 (group 1) and 1.4 (group 2), a significance lev-
el (alpha) of 0.050, and the use of a two-sided two-sample un-
equal-variance t-test. For group comparisons, SPSS Statistics 
v23.0 for Windows (IBM Corp., Armonk, NY, USA) and SAS 
v9.4 (SAS Inc., Cary, NC, USA) were used. For continuous data, 
t-test and Mann-Whitney U-test were applied for variables 
following normal and non-normal distributions, respectively. 
Chi-squared test or Fisher’s exact test was used for categorical 










Age (yr) 35.68±10.55 33.27±8.91 0.418
Sex (male:female) 6:16 9:13 0.340
Diagnosis
Allergic rhinitis 22 (100) 22 (100) -
Asthma 11 (50) 12 (54.6) 0.763
Allergic conjunctivitis 7 (31.8) 7 (31.8) >0.999
Atopic dermatitis 5 (22.7) 3 (13.7) 0.698
Rhinoconjunctivitis symptom score 10 (9–12) 9 (8–11) 0.205
Allergy testing
Total IgE (kU/L) 162.75 (63.3–457) 308 (157–524) 0.242
Blood eosinophils (cells/µL) 205 (100–460) 245 (170–400) 0.981
Wheal size to Dp (mm) 8.91±4.73 8.77±4.39 0.922
Specific IgE for Dp (kUA/L) 7.93 (1.58–10.20) 10.5 (3.83–24.50) 0.153
Indoor furry animals 7 (31.8) 5 (22.7) 0.498
Scoring of allergic rhinitis 
Symptom score 6.8±2.1 6.8±2.5 >0.999
Medication score 1 (0.1–2.0) 0.8 (0.0–1.0) 0.223
Visual analog scale 5.5 (4.2–6.9) 5.6 (4.5–6.8) 0.672
Quality of life 70.8±13.5 69±17.7 0.711
IgE, immunoglobulin E; Dp, dermatophagoides pteronyssinus.
Continuous data are expressed as mean±standard deviation or median (in-
terquartile range, 25 and 75 percentiles of data); categorical data are ex-
pressed as number (%). T-test was used for age and specific IgE for Dp; other 
continuous variables were compared via Mann-Whitney U-test. Chi-squared 
test was used for categorical data, except atopic dermatitis (Fisher’s exact test).
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data. Differing concentrations of PM were analyzed by place 
and group via linear mixed model. Outdoor and indoor PM 
levels were subjected to Pearson correlation analysis. Signifi-
cance was set at p<0.05.
RESULTS
Population characteristics    
Characteristics of the study population are shown in Table 1. 
No significant group-wise differences were observed. One MP 
group member dropped out of the study due to personal rea-
sons, but the two groups did not differ in intention-to-treat or 
per-protocol analysis.
Indoor (bedroom/living room) and outdoor 
environments
During the study period, the average bedroom PM2.5 concen-
tration was 27.2±4.4 μg/m3 (mean±standard deviation), which 
exceeded the WHO AQG limit. In living rooms, PM2.5 concen-
tration averaged 15.5±2.1 μg/m3 (Fig. 1A). Therefore, the bed-
room PM2.5 level was 1.8 times higher than that of the living 
room (p<0.001), surpassing the outdoor average (23.5±4.8 μg/
m3) as well. The mean bedroom PM10 concentration was 33.4± 
5.6 μg/m3, which was also higher than the living room level 
(18.1±2.5 μg/m3; p<0.001) (Fig. 1B). During this study, the out-
door PM10 concentration was 42.0±7.2 μg/m3 on average. The 
correlation between outdoor and indoor (bedroom and living 
room) levels is shown in Supplementary Table 1 (only online). 
Outdoor PM levels correlated better with determinations of 
the living room than with those of the bedroom. 
Improvement in indoor PM concentration after air 
purifier operation
Amelioration of bedroom PM levels after air purifier operation 
is shown in Fig. 2. Average PM2.5 concentration was reduced by 
51.8% (from 27.2±4.4 μg/m3 to 13.1±2.0 μg/m3; p=0.045) (Fig. 
2A). PM10 concentration also declined by 53.2% on average 
(from 33.4±5.6 μg/m3 to15.6±2.5 μg/m3; p=0.048) (Fig. 2B). 
Living room PM concentrations determined after air purifier 
operation are shown in Fig. 3. The mean PM2.5 level fell by 
30.5% (from 15.5±2.1 μg/m3 to 10.7±2.5 μg/m3; p=0.026) (Fig. 
3A), and PM10 concentration showed 30.7% improvement 































Fig. 1. Outdoor and indoor concentrations of PM2.5 (A) and PM10 (B) during study period. PM, particulate matter; WHO AQG, World Health Organization 
air quality guideline.
  Living room     Bed room     Outdoor     WHO AQG
  Living room     Bed room     Outdoor     WHO AQG
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scores improved similarly in both AP and MP groups (Fig. 5A, 
C, and D), but objective medication scoring showed signifi-
cantly greater improvement in the AP group at 6 weeks, com-
pared with placebo (Fig. 5B). AP group members registered a 
26.3% reduction in AR medication use at 6 weeks (p=0.033). 
These differences emerged in the third week of air purifier op-
eration and persisted until the end of the study. In addition, AP 
Table 2. Comparison of the Number of Days Exceeding WHO AQG Stan-
dards by Group
Mockup purifier 
(total of 924 days*)
Active purifier 
(total of 924 days*)
p value†
Bed room
PM2.5 (>25 μg/m3) 239 (25.9) 58 (6.3) <0.001
PM10 (>50 μg/m3)   94 (10.2) 18 (2.0) <0.001
Living room
PM2.5 (>25 μg/m3) 72 (7.8) 22 (2.4) <0.001
PM10 (>50 μg/m3)   8 (0.9) 14 (1.5) 0.200
PM, particulate matter; WHO AQG, World Health Organization air quality 
guideline.
*Total days: 22 sites (per group)×42 days (air purifier operation period), †p-val-
ue was calculated by chi-square test.
number of days at levels beyond the WHO AQG limits was sig-
nificantly lower after air purifier operation, especially in terms 
of bedroom PM2.5 concentrations (Table 2). Since this study in-
volved two South Korean cities that were 167.8 miles (270 km) 
apart, we also checked for city-wide differences in air quality 
before and after operating the air purifiers. However, we found 
no difference between the two cities. 
In addition to average PM concentrations, the exposure 
times to high concentrations of PM were significantly reduced 
after air purifier use. Due to various indoor activities, the con-
centration of fine dust was expected to surge and then dimin-
ish gradually (Fig. 4A, MP group depiction). However, PM lev-
els declined rapidly under such circumstances in AP (vs. MP) 
households. (Fig. 4B, AP group depiction). When calculated, 
the time required for PM2.5 concentration in bedrooms to fall 
from >150 μg/m3 to <25 μg/m3 (WHO threshold) was reduced 
by 38.1% (from 249.3±209.0 min to 153.6±187.9 min; p<0.001) 
(Fig. 4C).
Improvement in allergic rhinitis after operation of air 
purifiers









































Fig. 2. Changes in bedroom PM2.5 (A) and PM10 (B) concentrations after air purifier operation. PM, particulate matter; WHO AQG, World Health Organi-
zation air quality guideline.
  Mockup     Active     Outdoor     WHO AQG
  Mockup     Active     Outdoor     WHO AQG
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group members were using 1.26 times the AR medications used 
by the MP group at study onset. After 6 weeks of use, this figure 
was reduced to 0.67 times (p=0.033).
DISCUSSION
The results of this intricately designed study clearly demon-
strate that air purifiers are beneficial for adults with persistent 
AR, underscoring the importance of indoor air pollution as a 
critical environmental issue. Despite apparent placebo effect 
reflected in subjective measures, we nevertheless confirmed 
objective gains in AR medication scores for users of active air 
purifiers, as opposed to mockup devices. Therefore, managing 
indoor pollutants on an individual basis may have merit in AR 
patients. 
There are several explanations for the reduction of medica-
tion scores observed in this study. Air purifiers effectively re-
duce the levels of PM, a well-known risk factor in patients with 
allergic airway disease linked to indoor allergen exposure. Lev-
els of household PM are attributable to outdoor PM, cooking 
fumes, cigarette smoking, microorganisms, and other sources 
such as HDM allergens.20 Patient’s exposure times to high con-
centrations of PM are also significantly reduced by air purifier 
use; and PM2.5 concentrations, which may be especially nox-
ious to patients with allergic airway disease, are effectively re-
duced by air purification. It has been established that small-
caliber PM poses a comparatively greater health hazard. In one 
previous study, an increased hospitalization rate due to respi-
ratory diseases correlated more closely with PM2.5 than PM10 
levels.2 Most of the studies heretofore in PM over airway aller-
gy have been conducted in asthma,21,22 and the current study 
has the value to shed some light in the specific field of AR. 
The difference we encountered in PM concentrations of 
bedroom and living room spaces was an unexpected finding, 
and may constitute a relative breakthrough in indoor air pol-
lution management. Prior to this study, it was assumed that 
PM concentration in the living room (i.e., the gathering place 
and center of daily family activities) would exceed levels in 
more static bedroom environments. Moreover, the living room 
is closer to the kitchen, where cooking activity inordinately 
adds to the PM load. However, the opposite phenomenon was 
observed in this study. The higher levels of PM (both PM2.5 and 











































Fig. 3. Changes in living room PM2.5 (A) and PM10 (B) concentrations after air purifier operation. PM, particulate matter; WHO AQG, World Health Or-
ganization air quality guideline.
  Mockup     Active     Outdoor     WHO AQG
  Mockup     Active     Outdoor     WHO AQG
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be explained by the effect of ventilation rate, which is typically 
lower than the standard setting.23 Although differing bedroom 
and living room ventilation rates were not fully investigated, a 
lower ventilation rate may be anticipated in the bedroom by 
comparison. An alarming fact is that similar conditions may 
exist in nursing homes, hospitals, or nurseries, rendering dis-
advantaged, marginalized, or inactive occupants more vulner-
able to this type of indoor pollution. Further studies are need-
ed to gather more related evidence. However, this premise is 
untenable if outdoor air is unexpectedly tainted by forest fires, 
dust storms, or seasonal pollen peaks. 
Our data may also be applicable to other health conditions 
associated with PM, which presumably would benefit from 
the reductions achieved through air purification. PM is a re-
ported risk factor in asthma hospitalizations,6 cardiovascular 
disease/mortality,24 pediatric atopic dermatitis,25 emergency 
room visits,26 and lung cancer.27 Long-term exposure to PM is 
reportedly associated with mortality rates.28,29 Likewise, vari-
ous circulating inflammatory and thrombogenic indices,5 as 
well as stress hormone levels, have shown improvement in 
healthy patients after air purifier operation.30
Ultimately, this study had some limitations. First, the out-
door air of each home was not tested, and we relied instead 






















































































Fig. 4. Time taken to reduce PM2.5 concentration from 150 to 25 μg/m3. Representative PM 
levels in placebo group (A), active group (B), and comparison of reduction times between 
groups (C).  PM, particulate matter.
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observatory and residence locations (1.2 miles/1.9 kilometers 
on average) seemed acceptable for extrapolation. Another is-
sue is that the lifestyles (i.e., in-home exposure times, propor-
tionate bedroom/living room indoor occupancy, or cooking 
patterns and time spent in kitchens) of participants were not 
considered. Furthermore, we did not compare household in-
door allergen levels. An attempt at monitoring HDM allergens 
using the Petri dish method31 was unproductive. Therefore, it 
was impossible to determine whether AR medication scores 
improved due to lower allergen concentrations, PM concen-
trations, or both. Although allergic biomarkers were not mea-
sured in our study, further research about either nasal or serum 
biomarker changes will help to support out findings. Finally, we 
could not check the efficacy of purifiers in reducing the PM of 
smokers, as exposure to indoor smokers disqualified study 
candidates.
In conclusion, the findings in this study confirm that the use 
of air purifiers with HEPA filters may mitigate medication re-
quirements for patients with HDM-induced AR. We also de-
termined that interventional air purification significantly low-
ered indoor PM2.5 and PM10 levels, regardless of room location, 
ensuring an overall healthier environment. 
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Fig. 5. Changes in symptoms (A), medication use (B), visual analog scale (C), and quality of life scores (D) of allergic rhinitis after air purifier operation. 
Values are expressed as mean±standard deviation.
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